Effect And Quality Of Life Of 77 Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitor Analysis Of Influencing Factors

Objective:To explore the therapeutic effect,health-related quality of life and the influencing factors of chronic myeloid leukemia patients receiving tyrosine kinase inhibitor,and to provide scientific basis for improving the curative effect and improving the quality of life of patientsMethods:A retrospective collection about general data(age,sex,education level,ec onomic income,etc.),clinical characteristics,drug type,complications,medicati on compliance,test compliance,genetic test results,etc.of 77 patients diagnos ed as chronic myeloid leukemia in our department from march 2009 to march 2019 and followed up regularly in our outpatient clinic from march 2018 to de cember 2019.And health-related quality of life questionnaires were conducted during the outpatient follow-up period.All patients were informed and used S F-36 health status.Acceptance of tyrosine based on results analysis efficacy,h ealth-related quality of life,and influencing factors in patients with chronic my eloid leukemia with kinase inhibitorsResults:The average age was 50.53±14.12 years;24 cases had complications witho ut complications;46 cases had complications without complications;31 cases h ad Sokal scores(61 cases in low-risk group,7 cases in middle-risk group and 9 cases in high-risk group);and the average duration of TKI drug treatment was 43.86±25.90 months,taking drugs(1 generation tyrosine kinase inhibitor i matinib:31 cases of glipenil,18 cases of norrinin,7 cases of xinwei,2 genera tion tyrosine kinase inhibitor nilotinib:21 cases of dahina);tiredness The total hematological response(CHR)rate was 98.70%(76/77),the cytogenetic response rate(CCyR)for 3 months,6 months and 12 months:50.64%(39/77),71.43%(55/77),87.01%(67/77),and the cumulative complete cytogenetic response rate(C CyR)was 97.40%(75/77).3 months,6 months,12 months major molecular rea ction rate(MMR):3.90%(3/77),20.72%(15/77),38.96%(30/77),tired the primary molecular response rate(MMR)was 77.62%(59/77),the cumulative molecular r esponse rate(MR4.0 or MR4.5)was 61.04%(47/77),the cumulative progression-free survival rate(PFS)was 97.40(75/77),and the overall survival rate(OS)was 100%.The factors influencing the main molecular response rate were age,education,complications,drug type,Sokal score and compliance(P<0.05).the lower,the better the medication compliance,the more patients can reach the main molecular response.the patients who use the second generation TKI drug s have a higher rate of major molecular response,and the MMR duration is lo nger than the TKI of the first generation,the difference is statistically significa nt(P<0.05).MMR duration averaged 26.97±25.26 months.The analysis MMR duration and its influencing factors showed that the duration of 1 MMR was r elated to the type of TKI drugs,and the MMR duration of the second generati on of TKI drugs was longer than that of the first generation of drugs,the diff erence was statistically significant(P<0.05).2 General causes affecting MMR d uration with age,risk stratification of Sokal score,medication compliance,test compliance,the difference was statistically significant(P<0.05).77 questionnaires were issued,77 valid questionnaires were collected,and the recovery rate was 100%.SF—36 quality of life scale of patients with chro nic myeloid leukemia is divided into eight dimensions:physiological function,physiological function,somatic pain,general health status,energy,social functio n,emotional function and mental health.According to the results,the scores of physiological function,physiological function,general health status,energy,em otional function and mental health were lower than those of the national norm(P<0.05).The higher the vocational education,no complications,no complica tions,the better the medication compliance,the better the test compliance,the higher the quality of life score,the difference was statistically significant(P<005).The group analysis of oral drugs showed that the quality TKI life score o f the second generation was higher than that of the first generation TKI drugs,the difference was statistically significant,and the Sokal score was not signifi cantly related to the quality of life related to healthAnalysis of the correlation between the clinical efficacy of tyrosine kinas e inhibitors in patients with chronic myelogenous leukemia and some health-rel ated quality of life dimensions showed that there was a positive correlation bet ween the two,that is,the higher the score of physiological function,general h ealth status,energy and mental health,the more the major molecular remission was achieved(P<0.05)Conclusion:1.The clinical efficacy of 77 patients with chronic myeloid leukemia:the cumu lative complete hematological response(CHR)rate was 98.70%(76/77),and the cytogenetic response rate(CCyR)for 3 months,6 months,12 months:50.64%(39/77),71.43%(55/77),87.01%(67/77),and the cumulative complete cytogeneti c response rate(CCyR)was 97.40%(75/77).3 months,6 months,12 months m ajor molecular reaction rate(MMR):3.90%(3/77),20.72%(15/77),38.96%(30/77)th e cumulative major molecular response rate(MMR)was 77.62%(59/77),the cu mulative molecular response rate(MR4.0 or MR4.5)was 61.04%(47/77),the cu mulative progression-free survival rate(PFS)was 97.40(75/77)and the overall survival rate(OS)was 100%2 Clinical efficacy of chronic myeloid leukemia is related to age,education,co mplications,medication compliance and risk stratification of Sokal score.MMR duration averaged 26.97±25.26 months.MMR duration was related to drug type,age,risk stratification of Sokal score,medication compliance,test compliance 3 Second-generation TKI drugs enable faster and deeper molecular remission in patients with chronic myeloid leukemia;4 Compared with the domestic norm,the quality of life of patients with chroni c myeloid leukemia is generally poor;5 The patient's economic status,professional education,complications,complicat ions,compliance with medication and compliance with tests have a great impa ct on the quality of life;6 The quality of life of patients taking second-generation TKI drugs is better t han that of first-generation TKI drugs;7 There is a positive correlation between clinical efficacy and quality of life in patients with chronic myeloid leukemia.